138 related articles for article (PubMed ID: 22401656)
1. Molecular pathways and crosstalk characterizing the cardiorenal syndrome.
Mühlberger I; Mönks K; Fechete R; Mayer G; Oberbauer R; Mayer B; Perco P
OMICS; 2012 Mar; 16(3):105-12. PubMed ID: 22401656
[TBL] [Abstract][Full Text] [Related]
2. Cardiorenal syndrome type 4: From chronic kidney disease to cardiovascular impairment.
Granata A; Clementi A; Virzì GM; Brocca A; de Cal M; Scarfia VR; Zanoli L; Ronco C; Corrao S; Malatino L
Eur J Intern Med; 2016 May; 30():1-6. PubMed ID: 26961461
[TBL] [Abstract][Full Text] [Related]
3. Cardiorenal syndrome type 4: management.
Clementi A; Virzì GM; Brocca A; de Cal M; Vescovo G; Granata A; Ronco C
Blood Purif; 2013; 36(3-4):200-9. PubMed ID: 24496191
[TBL] [Abstract][Full Text] [Related]
4. Cardiorenal Syndrome and the Role of the Bone-Mineral Axis and Anemia.
Charytan DM; Fishbane S; Malyszko J; McCullough PA; Goldsmith D
Am J Kidney Dis; 2015 Aug; 66(2):196-205. PubMed ID: 25727384
[TBL] [Abstract][Full Text] [Related]
5. Cardiorenal syndrome: role of protein-bound uremic toxins.
Lekawanvijit S; Krum H
J Ren Nutr; 2015 Mar; 25(2):149-54. PubMed ID: 25556308
[TBL] [Abstract][Full Text] [Related]
6. Micronutrients and cardiorenal disease: insights into novel assessments and treatment.
McCullough PA
Blood Purif; 2011; 31(1-3):177-85. PubMed ID: 21228587
[TBL] [Abstract][Full Text] [Related]
7. Cardiorenal Syndrome in End-Stage Kidney Disease.
Tsuruya K; Eriguchi M; Yamada S; Hirakata H; Kitazono T
Blood Purif; 2015; 40(4):337-43. PubMed ID: 26657922
[TBL] [Abstract][Full Text] [Related]
8. Novel Perspectives in Chronic Kidney Disease-Specific Cardiovascular Disease.
Xu C; Tsihlis G; Chau K; Trinh K; Rogers NM; Julovi SM
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473905
[TBL] [Abstract][Full Text] [Related]
9. The cardiorenal syndrome: a mutual approach to concomitant cardiac and renal failure.
Ben-Shoshan J; Entin-Meer M; Guzner-Gur H; Keren G
Isr Med Assoc J; 2012 Sep; 14(9):570-6. PubMed ID: 23101423
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms of protein-bound uremic toxin-mediated cardiac, renal and vascular effects: underpinning intracellular targets for cardiorenal syndrome therapy.
Savira F; Magaye R; Hua Y; Liew D; Kaye D; Marwick T; Wang BH
Toxicol Lett; 2019 Jun; 308():34-49. PubMed ID: 30872129
[TBL] [Abstract][Full Text] [Related]
11. Molecular models of the cardiorenal syndrome.
Heinzel A; Fechete R; Mühlberger I; Perco P; Mayer B; Lukas A
Electrophoresis; 2013 Jun; 34(11):1649-56. PubMed ID: 23494759
[TBL] [Abstract][Full Text] [Related]
12. Kidney and heart interactions during cardiorenal syndrome: a molecular and clinical pathogenic framework.
Napoli C; Casamassimi A; Crudele V; Infante T; Abbondanza C
Future Cardiol; 2011 Jul; 7(4):485-97. PubMed ID: 21797745
[TBL] [Abstract][Full Text] [Related]
13. Cardiorenal syndrome in chronic kidney disease.
Tsuruya K; Eriguchi M
Curr Opin Nephrol Hypertens; 2015 Mar; 24(2):154-62. PubMed ID: 25636143
[TBL] [Abstract][Full Text] [Related]
14. Cardiorenal syndrome type 1: pathophysiological crosstalk leading to combined heart and kidney dysfunction in the setting of acutely decompensated heart failure.
Ronco C; Cicoira M; McCullough PA
J Am Coll Cardiol; 2012 Sep; 60(12):1031-42. PubMed ID: 22840531
[TBL] [Abstract][Full Text] [Related]
15. Type 4 cardiorenal syndrome.
Pinheiro da Silva AL; Vaz da Silva MJ
Rev Port Cardiol; 2016 Nov; 35(11):601-616. PubMed ID: 27712930
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular pathophysiology in chronic kidney disease: opportunities to transition from disease to health.
Tomey MI; Winston JA
Ann Glob Health; 2014; 80(1):69-76. PubMed ID: 24751567
[TBL] [Abstract][Full Text] [Related]
17. Cardio-Pulmonary-Renal Interactions: A Multidisciplinary Approach.
Husain-Syed F; McCullough PA; Birk HW; Renker M; Brocca A; Seeger W; Ronco C
J Am Coll Cardiol; 2015 Jun; 65(22):2433-48. PubMed ID: 26046738
[TBL] [Abstract][Full Text] [Related]
18. Cardiorenal interaction: appropriate treatment of cardiovascular risk factors to improve outcomes in chronic kidney disease.
McCullough PA; Verrill TA
Postgrad Med; 2010 Mar; 122(2):25-34. PubMed ID: 20203453
[TBL] [Abstract][Full Text] [Related]
19. Target organ cross talk in cardiorenal syndrome: animal models.
Bongartz LG; Braam B; Gaillard CA; Cramer MJ; Goldschmeding R; Verhaar MC; Doevendans PA; Joles JA
Am J Physiol Renal Physiol; 2012 Nov; 303(9):F1253-63. PubMed ID: 22914779
[TBL] [Abstract][Full Text] [Related]
20. Increased risk of cardiovascular complications in chronic kidney disease: a possible role of leptin.
Korolczuk A; Dudka J
Curr Pharm Des; 2014; 20(4):666-74. PubMed ID: 23688007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
